Editorial: It's Not About The Size Of Your Pipeline...
This article was originally published in Scrip
Executive Summary
Scrip affiliate Pharmaprojects has been on its annual field trip into the drug pipeline, and the data crunch shows that GlaxoSmithKline has held onto its position as the company with the most drugs in development for another year, despite a year-on-year drop in the number of drug candidates on its books from 258 to 242.